SG11201808992UA - Compositions and methods for the detection of host cell proteins - Google Patents

Compositions and methods for the detection of host cell proteins

Info

Publication number
SG11201808992UA
SG11201808992UA SG11201808992UA SG11201808992UA SG11201808992UA SG 11201808992U A SG11201808992U A SG 11201808992UA SG 11201808992U A SG11201808992U A SG 11201808992UA SG 11201808992U A SG11201808992U A SG 11201808992UA SG 11201808992U A SG11201808992U A SG 11201808992UA
Authority
SG
Singapore
Prior art keywords
international
compositions
pct
methods
april
Prior art date
Application number
SG11201808992UA
Other languages
English (en)
Inventor
Guojie Mao
Original Assignee
Lonza Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Ag filed Critical Lonza Ag
Publication of SG11201808992UA publication Critical patent/SG11201808992UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
SG11201808992UA 2016-04-14 2017-04-12 Compositions and methods for the detection of host cell proteins SG11201808992UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322621P 2016-04-14 2016-04-14
PCT/EP2017/058775 WO2017178526A1 (en) 2016-04-14 2017-04-12 Compositions and methods for the detection of host cell proteins

Publications (1)

Publication Number Publication Date
SG11201808992UA true SG11201808992UA (en) 2018-11-29

Family

ID=58645011

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808992UA SG11201808992UA (en) 2016-04-14 2017-04-12 Compositions and methods for the detection of host cell proteins

Country Status (13)

Country Link
US (3) US11353468B2 (pt)
EP (2) EP3443348A1 (pt)
JP (1) JP2019516964A (pt)
KR (1) KR102408260B1 (pt)
CN (2) CN115109148A (pt)
AU (1) AU2017251360A1 (pt)
BR (1) BR112018071107A2 (pt)
CA (1) CA3020808A1 (pt)
EA (1) EA201892325A1 (pt)
IL (2) IL290358B2 (pt)
MX (1) MX2018012550A (pt)
SG (1) SG11201808992UA (pt)
WO (1) WO2017178526A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017251360A1 (en) * 2016-04-14 2018-11-01 Lonza Ltd Compositions and methods for the detection of host cell proteins
US11268951B2 (en) * 2017-09-20 2022-03-08 Charles River Laboratories International, Inc. CHO host cell protein assay
CN109078628B (zh) * 2018-08-27 2021-06-11 西北大学 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用
CN111665364A (zh) * 2019-03-08 2020-09-15 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 一种评估hcp检测用多克隆抗体覆盖率的方法
KR20220107586A (ko) 2021-01-25 2022-08-02 금오공과대학교 산학협력단 전기신호를 이용한 세포수 검출장치 및 이를 이용한 검출방법
WO2024084264A1 (en) * 2022-10-17 2024-04-25 HAJIAN TEHRANI, Behrooz Immunoassay for detecting host cell proteins of high five cells
CN115894677A (zh) * 2022-12-01 2023-04-04 湖州申科生物技术股份有限公司 一种提高hcp检测抗体覆盖率的抗体组合及其应用
CN117192107A (zh) * 2023-09-11 2023-12-08 福建基诺厚普生物科技有限公司 一种工艺特异性宿主细胞蛋白残留的检测方法及试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US6797522B1 (en) * 1994-01-13 2004-09-28 The Trustees Of Columbia University In The City Of New York Synthetic receptors
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
EP1044378A2 (en) * 1997-12-31 2000-10-18 Genentech, Inc. Real-time monitoring of an analyte by chromatography using an on-line assay
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20030091976A1 (en) * 2001-11-14 2003-05-15 Ciphergen Biosystems, Inc. Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry
EP1616180A4 (en) * 2003-04-22 2006-07-19 Ciphergen Biosystems Inc ANALYSIS PROCESS FOR HOST CELL PROTEINS
WO2005071410A1 (en) * 2004-01-13 2005-08-04 Tanox, Inc. Detecting and quantifying host cell proteins in recombinant protein products
US8728828B2 (en) * 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
CN101571549B (zh) * 2008-04-30 2013-08-14 上海泽润生物科技有限公司 Vero细胞HCP检测试剂盒及其应用
JP5808249B2 (ja) * 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
CN104755489B (zh) * 2012-10-30 2019-01-15 弗·哈夫曼-拉罗切有限公司 使用双级切线流超滤纯化多肽
CN103439512B (zh) * 2013-07-30 2014-05-07 通化东宝药业股份有限公司 一种检测特异性重组人胰岛素大肠杆菌残留宿主蛋白的方法
EP3683232A1 (en) * 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
CN103792366B (zh) * 2014-01-21 2015-09-23 内蒙古必威安泰生物科技有限公司 口蹄疫疫苗宿主细胞蛋白双抗夹心酶联免疫检测试剂盒及使用方法
CN105021824A (zh) * 2015-07-06 2015-11-04 上海优者生物科技有限公司 用于定量检测生物医药制品中残留cho宿主细胞蛋白的elisa试剂盒及其使用方法
AU2017251360A1 (en) 2016-04-14 2018-11-01 Lonza Ltd Compositions and methods for the detection of host cell proteins

Also Published As

Publication number Publication date
EP3443348A1 (en) 2019-02-20
MX2018012550A (es) 2019-07-08
US20190128903A1 (en) 2019-05-02
KR102408260B1 (ko) 2022-06-10
EA201892325A1 (ru) 2019-04-30
KR20180129927A (ko) 2018-12-05
US20220268791A1 (en) 2022-08-25
IL290358B1 (en) 2023-11-01
IL290358A (en) 2022-04-01
JP2019516964A (ja) 2019-06-20
IL290358B2 (en) 2024-03-01
US20220268792A1 (en) 2022-08-25
IL262297A (en) 2018-11-29
EP3683579A1 (en) 2020-07-22
CA3020808A1 (en) 2017-10-19
US11353468B2 (en) 2022-06-07
CN115109148A (zh) 2022-09-27
CN109564217A (zh) 2019-04-02
AU2017251360A1 (en) 2018-11-01
BR112018071107A2 (pt) 2019-04-16
WO2017178526A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
SG11201808992UA (en) Compositions and methods for the detection of host cell proteins
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201909777YA (en) Modulatory polynucleotides
SG11201909868YA (en) Compositions and methods of treating huntington's disease
SG11201804696RA (en) Techniques for metadata processing
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201907162TA (en) Methods for cell-type specific profiling to identify drug targets
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201909011PA (en) Niraparib compositions
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201809331RA (en) Antibodies recognizing tau
SG11201811015RA (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
SG11201407508RA (en) Encoding and decoding based on blending of sequences of samples along time
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201901140QA (en) Compounds and methods for reducing tau expression
SG11201901172QA (en) A method for manufacturing a fuel component
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201804704PA (en) Compositions and methods for decreasing tau expression